Printer Friendly

Covering ground: from the negotiating table to the lab to the production line, we've got it covered.

The end-to-end service model is talked about a lot these days, driven in part by the need to simplify and streamline supply chains, generate cost savings and optimize performance. We talked to Ian Muir, managing director from Aesica about this trend (page30), the company having recently completed a new development center, which now allows it to offer end-to-end service from a single location.

The topic got me thinking that it's sort of what we do here at Contract Pharma: provide our readers with glimpses and insights into the market from one end to the other and this issue is a perfect example. We cover a lot of ground, all the way from the negotiating table, to development in the lab, to manufacturing operations and drug delivery trends all the way to tracking and tracing products once they leave the warehouse and make their way to the shelf.

In "Solid Dispersions: A universal formulation strategy for poorly soluble drugs?," Robert Harris, chief technical officer of Juniper Pharma Services discusses how drug solubility continues to be a challenge for pharmaceutical scientists. He says many of the new drug compounds emanating from drug discovery pipelines are poorly water-soluble and in fact, he says it is estimated that up to 80% of new small molecule drugs in development can be regarded as poorly soluble. Beginning on page 32 Mr. Harris talks about several techniques that can be used to improve drug solubility.

Experts from PharmaCircle LLC (page 46) explore the trend of pharma increasingly embracing injectables as a preferred form of delivery. In "Injectables: The New Oral?," the authors explore the trends behind this sharp move towards injectables saying, in fact, seven of the top 10 pharmaceuticals by sales in 2014 were injectables, when only a decade earlier there was only one, Amgen's Epogen.

In the complex world of contract negotiations, negotiating supply agreements between biopharma CMOs and their clients is typically long and costly. Beginning on page 42, in "Biopharmaceutical Contract Manufacturing Contract Negotiations,"William Downey, president of HighTech Business Decisions, offers valuable insight into the most difficult areas in these contract negotiations as seen from the perspective of executives at a number of pharma and biotech companies as well as CMOs.

Moving on, in "CMO Systems" (page 52), Phil Burns, cofounder of CRO-Consulting defines how to establish and maintain the internal systems for a company's CMO activities. Highlighted are regulatory, technical, compliance and operational systems for any CMO activity and the article also explores how to pursue innovation during the efforts.

Another current hot topic in the pharma world is continuous manufacturing, which we cover beginning on page 37. Girish Malhotra, president of EPCOT International, gives us a close look at the unique characteristics of continuous processes in pharmaceutical manufacturing and addresses key points that pose challenges with continuous manufacturing and regulatory compliance. He says in addition to continuous processes having very unique characteristics compared to any other manufacturing process, they also have a very stringent demand: qualify has to be built in the process from the start.

As always, in an effort to bring you the relevant and important information to help with your business endeavors, we've covered a lot of ground in this issue. If there are any topics and/or ideas you have for articles or want to read about, drop me a line.

Tim Wright, Editor

twright@rodmanmedia.com
COPYRIGHT 2016 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FROM THE EDITOR
Author:Wright, Tim
Publication:Contract Pharma
Date:Apr 1, 2016
Words:561
Previous Article:How to build better proteins: advancing the next generation of biologics.
Next Article:DPT, confab complete $10m investment.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters